Relay raises $63M in series B

Relay Therapeutics Inc. (Cambridge, Mass.) raised $63 million in a series B round led by BVF Partners. Fellow new investors GV (formerly Google Ventures), Casdin Capital, EcoR1 Capital and Section 32 also participated, as did existing investors Third Rock Ventures and Alexandria Venture Investments.

Relay told BioCentury it expects to begin clinical testing in 2019 of its first program, which is in oncology. Using a discovery platform that integrates biology, chemistry, biophysics and computational capabilities, Relay essentially creates video simulations of proteins as they undergo conformational changes in vivo, and identifies allosteric binding sites on proteins previously deemed intractable (see BioCentury, Sept. 19, 2016)...